Masatoshi Kudo, MD from Kindai University, Japan discusses TACE new cancer region is not failure and TACE + Sorafenib should be continued even after new cancer at the 2018 Gastrointestinal Cancers Symposium.
TACE New Cancer Region Is Not Failure – TACE + Sorafenib Should Be Continued Even After New Cancer
